Business Development

Arcturus Business Development Opportunities

Arcturus Therapeutics is actively engaged in partnering discussions. Please contact
BD@ArcturusRx.com regarding any business development opportunities.
Partnered RNA Medicines

Partnered RNA Medicines

Logo
LUNAR®-HBV
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR® lipid-mediated delivery platform and UNA oligomer chemistry. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
Logo
COVID-19 Vaccine
In March 2020, we partnered with Duke-NUS Medical School to develop a COVID-19 vaccine for the Singapore Economic Development Board (“EDB”) based on the Company’s STARR Technology and designated the vaccine candidate LUNAR®-COV19 (ARCT-021). Duke-NUS Medical School is a graduate entry medical school in Singapore, established in 2005 through a partnership between Duke University School of Medicine and the National University of Singapore (“NUS”).
Logo
COVID-19 Vaccine
In October 2020, we were awarded a grant from the EDB to support the further development of our LUNAR®-COV19 vaccine candidate. In November 2020, we announced a manufacturing support agreement with the EDB.
Logo
LUNAR®-NASH
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly owned therapeutic delivery platform, LUNAR®.
Logo
LUNAR®-GSDIII and LUNAR®RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx. Ultragenyx has advanced LUNAR®-GSDIII into clinical development.
Logo
In August 2021, we announced an agreement with Vingroup, to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam. Under the agreement, Vinbiotech will build out a manufacturing facility in Vietnam, and we will provide to Vinbiotech access to proprietary technologies and processes for the manufacture of Arcturus’ investigational COVID-19 vaccines. The license and technology transfer applies toward drug product manufacturing.
Internal Programs

Internal Programs

Logo
LUNAR®-OTC
The LUNAR®-OTC (ARCT-810) development program addresses ornithine transcarbamylase (“OTC”) deficiency, a rare, genetic disease caused by mutations in the OTC gene that lead to dysfunctional or deficient OTC levels. Our LUNAR®-OTC development candidate, ARCT-810, uses our LUNAR® platform to deliver normal OTC mRNA into liver cells, where OTC is produced and functions, to produce normal functioning OTC with possible disease-modifying effects. Our LUNAR®-OTC approach has the potential to treat the underlying defect that causes the debilitating symptoms of OTC deficiency, rather than mitigating symptoms by sequestering ammonia. LUNAR®-OTC has received orphan drug designation from the FDA for treatment of OTC deficiency. LUNAR®-OTC has received approval from the UK Health Research Authority to initiate a Phase 2 clinical study. Worldwide development and commercialization rights to ARCT-810 are entirely held by Arcturus.
Logo
LUNAR®-CF (ARCT-032 Grant by CFF)
ARCT-032 (LUNAR®-CF) LUNAR®- program addresses cystic fibrosis lung disease, a progressive lung disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (“CFTR”) gene. In December 2020, we announced the selection and advancement of ARCT-032 as a development candidate for treatment of cystic fibrosis. ARCT-032 uses our LUNAR® platform to deliver codon-optimized CFTR mRNA into airway epithelial cells. This allows airway cells to produce functional CFTR protein using their native translational machinery and protein trafficking pathways. This approach has the potential to treat the underlying defect that causes CF lung disease, regardless of what mutation type a patient has. The Cystic Fibrosis Foundation (“CFF”) has recognized the potential of the LUNAR®-CF program and has partnered with us to develop this important therapy. ARCT-032 represents the first LUNAR®-based mRNA therapeutic that will be delivered by the inhaled route, offering direct delivery to the affected airways with the potential to restore functional CFTR. We have announced selection of a development candidate and plan to initiate a CTA in 2022.
Technology Platforms

Technology Platforms

Arcturus’ versatile RNA therapeutics and LNP Delivery Systems platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China and other countries). These technologies are potentially available for licensing as part of a collaboration. Please contact BD@ArcturusRx.com regarding any business development opportunities.
  • LUNAR® LNP Lipid-mediated delivery
  • STARR™ mRNA Technology
  • RNA Manufacturing Expertise

Partnered RNA Medicines

Logo
LUNAR®-HBV
In October 2017, Arcturus entered into a partnership with Janssen, a Johnson & Johnson company, to develop and commercialize nucleic acid-based drug products for the treatment of specified diseases, including HBV, using Arcturus’ LUNAR® lipid-mediated delivery platform and UNA oligomer chemistry. Under the agreement, facilitated by J&J Innovation, Arcturus received an upfront cash payment and will receive R&D support, as well as pre-clinical, development, and sales milestone payments, and royalty payments on any future licensed product sales. Janssen will assume responsibility for development costs and all commercialization costs associated with the program.
Logo
COVID-19 Vaccine
In March 2020, we partnered with Duke-NUS Medical School to develop a COVID-19 vaccine for the Singapore Economic Development Board (“EDB”) based on the Company’s STARR Technology and designated the vaccine candidate LUNAR®-COV19 (ARCT-021). Duke-NUS Medical School is a graduate entry medical school in Singapore, established in 2005 through a partnership between Duke University School of Medicine and the National University of Singapore (“NUS”).
Logo
COVID-19 Vaccine
In October 2020, we were awarded a grant from the EDB to support the further development of our LUNAR®-COV19 vaccine candidate. In November 2020, we announced a manufacturing support agreement with the EDB.
Logo
LUNAR®-NASH
In December 2016, Arcturus entered into a partnership with Takeda to develop RNA-based therapeutic candidates for the treatment of NASH and other GI-related disorders, utilizing Arcturus’ wholly owned therapeutic delivery platform, LUNAR®.
Logo
LUNAR®-GSDIII and LUNAR®RARE
In October 2015, Arcturus has partnered with Ultragenyx Pharmaceutical, Inc. to develop RNA medicines that treat rare diseases. This collaboration combines Arcturus’ expertise in RNA medicines with Ultragenyx’ proven ability in rare disease drug development. In this partnership, Arcturus is exploiting the versatility of our proprietary Lipid-enabled and Unlocked Nucleic Acid modified RNA (LUNAR®) lipid-mediated delivery platform to design and optimize mRNA medicines for rare disease targets. These medicines will be developed and commercialized by Ultragenyx. Ultragenyx has advanced LUNAR®-GSDIII into clinical development.
Logo
In August 2021, we announced an agreement with Vingroup, to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within Vietnam. Under the agreement, Vinbiotech will build out a manufacturing facility in Vietnam, and we will provide to Vinbiotech access to proprietary technologies and processes for the manufacture of Arcturus’ investigational COVID-19 vaccines. The license and technology transfer applies toward drug product manufacturing.

News & Events

August 1, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
May 9, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 5, 2022
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
April 27, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 20, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
March 25, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
February 28, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
February 16, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 8, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
January 25, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
December 16, 2021
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
December 13, 2021
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
November 22, 2021
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
November 18, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 8, 2021
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
October 25, 2021
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
October 21, 2021
Arcturus Therapeutics Announces Leadership Appointments
October 20, 2021
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern